TY - JOUR T1 - Thromboelastography parameters in Italian pregnant women: do antithrombotic drugs change reference values? JF - Journal of Investigative Medicine JO - J Investig Med SP - 902 LP - 905 DO - 10.1136/jim-2019-001261 VL - 68 IS - 4 AU - Giovanni Luca Tiscia AU - Antonio De Laurenzo AU - Filomena Cappucci AU - Giovanni Favuzzi AU - Elena Chinni AU - Pasquale Vaira AU - Angelo Ostuni AU - Maurizio Margaglione AU - Elvira Grandone Y1 - 2020/04/01 UR - http://hw-f5-jim.highwire.org/content/68/4/902.abstract N2 - This study was carried out to explore hemostasis modifications occurring in pregnant women and thromboelastography profiles in those taking antithrombotic drugs. An exploratory study was carried out in the period from March 2017 to May 2018. Caucasian women from Southern Italy were recruited during a routine obstetric assessment. Participants were divided into four groups: T1 (gestational week <14 weeks), T2 (14–28 weeks), T3 (29–42 weeks) and T4 in the postpartum period. We investigated thromboelastography profile in 19 and 5 women administered with low-molecular-weight heparin or low-dose aspirin, respectively. “MA” value observed in the T1 group was significantly greater than that observed in the T3 and the T4 groups, while “K” in the T1 group was significantly longer than that in the T3 and the T4 groups, indicating a gradual development of a prothrombotic state (in all cases Mann-Whitney U test, p<0.05). Significant differences within “R” were observed between the T2 and the T3 and between the T3 and the T4 (“R” parameter) (Mann-Whitney U test, p<0.05). “LY30” parameter resulted to be significantly higher in the T1 group (Mann-Whitney U test, p=0.01) compared with the T4 one, indicating fibrinolysis decreases throughout pregnancy and until post partum. No significant variations were found in women administered with prophylactic doses of low-molecular-weight heparin. Significantly higher fibrinolysis (p<0.01) was observed for “LY30” parameter in women taking low-dose aspirin versus women not taking any treatments. Our data contribute to better interpret thromboelastography profile in the context of peripartum complications, which are often unpredictable and need prompt therapies. ER -